Study Tags Enzyme as New Prognostic Factor for Mesothelioma, According to Surviving Mesothelioma

Share Article

Cancer Researchers say an enzyme linked with some kinds of blood cancer could be used to help determine prognosis in patients with malignant pleural mesothelioma.

Mesothelioma Prognosis Linked to CD10

Enzyme May Help is Mesothelioma Prognosis

Overall survival for patients with positive CD10 expression was significantly shorter than that for patients with negative CD10 expression.

Scientists in New York have just released the findings of a new study suggesting that an enzyme called CD10 might work as an additional prognostic indicator for mesothelioma. Click here to read the full story on the Surviving Mesothelioma website.

Doctors at Memorial Sloan Kettering Cancer Center in New York tested 176 mesothelioma tissue samples for CD10 and found that the most aggressive cases were all positive for the enzyme.

“Overall survival for patients with positive CD10 expression was significantly shorter than that for patients with negative CD10 expression in all patients,” writes lead author Kyuichi Kadoka, MD, PhD.

Currently, cancer stage and histological subtype are the two primary factors used to determine the prognosis for people with pleural mesothelioma. Adding CD10 could make the process more effective.

“Prognosis is not just about lifespan. Having some idea of how a patient’s mesothelioma is likely to progress can give doctors insights into how best to treat it and can help patients make important decisions,” says Alex Strauss, Surviving Mesothelioma’s Managing Editor.

A total of 176 mesothelioma cases were evaluated for the CD10 study, which was published in the Annals of Surgical Oncology. To read more about CD10’s potential role in prognosis, see Enzyme May Help Doctors Determine Mesothelioma Prognosis, now available on the Surviving Mesothelioma website.

Kadoka, K et al, “Tumoral CD10 Expression Correlates with Aggressive Histology and Prognosis in Patients with Malignant Pleural Mesothelioma”, January 22, 2015, Annals of Surgical Oncology, Epub ahead of print,

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website